Skip to main content
. Author manuscript; available in PMC: 2014 Mar 14.
Published in final edited form as: Antibodies (Basel). 2012 Jul 4;1(2):149–171. doi: 10.3390/antib1020149

Figure 7.

Figure 7

RFA and huKS-IL2 IC synergize in induction of antitumor effects. Balb/c mice (7–8 mice per group) received 5 × 105 CT26-KS cells s.c. in the abdomen on d0. Mice were treated with partial RFA (25 seconds, d11), KS-IL2 IC (15 µg, d11–15), or both RFA and KS-IL2. Data shown are mean tumor volume ± SEM (A) or survival (B). The results are representative of 3 experiments. (Adapted from Johnson et al, 2008 [91]).